Low tigecycline concentrations in the cerebrospinal fluid of a neutropenic patient with inflamed meninges.
作者信息
Lengerke Claudia, Haap Michael, Mayer Frank, Kanz Lothar, Kinzig Martina, Schumacher Ulrike, Sörgel Fritz, Riessen Reimer
出版信息
Antimicrob Agents Chemother. 2011 Jan;55(1):449-50. doi: 10.1128/AAC.00635-10. Epub 2010 Oct 11.
Abstract
摘要
相似文献
1
Low tigecycline concentrations in the cerebrospinal fluid of a neutropenic patient with inflamed meninges.一名患有炎症性脑膜炎的中性粒细胞减少患者脑脊液中的替加环素浓度较低。
Antimicrob Agents Chemother. 2011 Jan;55(1):449-50. doi: 10.1128/AAC.00635-10. Epub 2010 Oct 11.
2
Cerebrospinal fluid penetration of tigecycline.替加环素的脑脊液穿透性。
Scand J Infect Dis. 2014 Jan;46(1):69-72. doi: 10.3109/00365548.2013.837957. Epub 2013 Oct 16.
3
Determination of atypical nonlinear plasma−protein-binding behavior of tigecycline using an in vitro microdialysis technique.使用体外微透析技术测定替加环素非典型的非线性血浆-蛋白结合行为。
J Pharm Sci. 2014 Mar;103(3):1013-9. doi: 10.1002/jps.23872. Epub 2014 Jan 24.
4
Results of tigecycline trials announced.替加环素试验结果公布。
Lancet Infect Dis. 2004 Dec;4(12):717. doi: 10.1016/s1473-3099(04)01219-8.
5
Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective.用替加环素治疗复发性泌尿道脓毒症：药理学视角
J Clin Microbiol. 2008 May;46(5):1892-3. doi: 10.1128/JCM.02494-07.
6
In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.替加环素、米诺环素及黏菌素-替加环素联合用药对鲍曼不动杆菌多重耐药及泛耐药临床分离株的体外活性
Antimicrob Agents Chemother. 2009 Mar;53(3):1295-6. doi: 10.1128/AAC.01097-08. Epub 2008 Dec 15.
7
Tigecycline: place in therapy and important considerations.替加环素：在治疗中的地位及重要考量因素
Am J Health Syst Pharm. 2006 Jul 1;63(13):1233. doi: 10.2146/ajhp060206.
8
Is there a future for tigecycline?替加环素的未来会怎样？
Intensive Care Med. 2014 Jul;40(7):1039-45. doi: 10.1007/s00134-014-3343-3. Epub 2014 May 29.
9
Ultrasonography-driven combination antibiotic therapy with tigecycline significantly increases survival among patients with neutropenic enterocolitis following cytarabine-containing chemotherapy for the remission induction of acute myeloid leukemia.超声引导下替加环素联合抗生素治疗显著提高了急性髓系白血病诱导缓解含阿糖胞苷化疗后中性粒细胞减少性小肠结肠炎患者的生存率。
Cancer Med. 2017 Jul;6(7):1500-1511. doi: 10.1002/cam4.1063. Epub 2017 May 26.
10
High serum concentrations of cyclosporin related to administration of tigecycline.血清中环孢素浓度升高与替加环素的使用有关。
Eur J Clin Pharmacol. 2009 Jan;65(1):101-3. doi: 10.1007/s00228-008-0557-8. Epub 2008 Sep 16.
引用本文的文献
1
Intrathecal or Intraventricular Tigecycline Therapy for Central Nervous System Infection Associated with Carbapenem-Resistant .鞘内或脑室内使用替加环素治疗与耐碳青霉烯类相关的中枢神经系统感染
Infect Drug Resist. 2022 Dec 9;15:7219-7226. doi: 10.2147/IDR.S387346. eCollection 2022.
2
Evaluation of the Synergistic Antibacterial Effects of Fosfomycin in Combination with Selected Antibiotics against Carbapenem-Resistant .磷霉素与选定抗生素联合使用对耐碳青霉烯类细菌的协同抗菌作用评估
Pharmaceuticals (Basel). 2021 Feb 25;14(3):185. doi: 10.3390/ph14030185.
3
Targeting the Blood-Brain Barrier to Prevent Sepsis-Associated Cognitive Impairment.靶向血脑屏障以预防脓毒症相关的认知障碍。
J Cent Nerv Syst Dis. 2019 Apr 9;11:1179573519840652. doi: 10.1177/1179573519840652. eCollection 2019.
4
Antibiotic Distribution into Cerebrospinal Fluid: Can Dosing Safely Account for Drug and Disease Factors in the Treatment of Ventriculostomy-Associated Infections?抗生素向脑脊液中的分布：在治疗脑室相关性感染时，药物和疾病因素的剂量调整是否安全？
Clin Pharmacokinet. 2018 Apr;57(4):439-454. doi: 10.1007/s40262-017-0588-3.
5
Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.抗菌药物在脑脊液中的临床药代动力学。
Clin Pharmacokinet. 2013 Jul;52(7):511-42. doi: 10.1007/s40262-013-0062-9.
本文引用的文献
1
Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.药物穿透血脑屏障/血脑脊液屏障以治疗中枢神经系统感染。
Clin Microbiol Rev. 2010 Oct;23(4):858-83. doi: 10.1128/CMR.00007-10.
2
Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline.婴儿期耐万古霉素粪肠球菌性脑膜炎：该病原体的特征及脑室注射达托霉素联合静脉注射替加环素的成功治疗。
Pediatr Infect Dis J. 2010 Apr;29(4):379-81. doi: 10.1097/INF.0b013e3181c806d8.
3
Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis.替加环素治疗两例多重耐药鲍曼不动杆菌性脑膜炎。
Int J Infect Dis. 2010 Sep;14 Suppl 3:e224-6. doi: 10.1016/j.ijid.2009.07.022. Epub 2009 Dec 3.
4
In vitro antibacterial activity of tigecycline against resistant Gram-negative bacilli and enterococci by time-kill assay.通过时间杀菌试验检测替加环素对耐药革兰氏阴性杆菌和肠球菌的体外抗菌活性。
Diagn Microbiol Infect Dis. 2009 Jul;64(3):300-4. doi: 10.1016/j.diagmicrobio.2009.03.023.
5
Multidrug resistant Acinetobacter nosocomial meningitis treated successfully with parenteral tigecycline.经胃肠外给予替加环素成功治疗多重耐药鲍曼不动杆菌医院获得性脑膜炎。
Ann Saudi Med. 2007 Nov-Dec;27(6):456-8. doi: 10.5144/0256-4947.2007.456.
6
Population pharmacokinetics of tigecycline in healthy volunteers.替加环素在健康志愿者中的群体药代动力学。
J Clin Pharmacol. 2007 Jun;47(6):727-37. doi: 10.1177/0091270007300263.
7
Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.单次100毫克剂量后替加环素的血清、组织和体液浓度。
J Antimicrob Chemother. 2006 Dec;58(6):1221-9. doi: 10.1093/jac/dkl403. Epub 2006 Sep 29.
8
Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.从美国住院患者中分离出的病原体的抗菌药敏性以及新型甘氨酰环素类抗菌药物替加环素的体外活性。
Antimicrob Agents Chemother. 2006 Oct;50(10):3479-84. doi: 10.1128/AAC.00210-06.
9
In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).替加环素对全球替加环素评估与监测试验（TEST项目，2004年）中6792株革兰氏阴性和革兰氏阳性临床分离菌株的体外活性。
Diagn Microbiol Infect Dis. 2005 Jul;52(3):215-27. doi: 10.1016/j.diagmicrobio.2005.06.001.
10
Tigecycline.替加环素
J Antimicrob Chemother. 2005 Sep;56(3):470-80. doi: 10.1093/jac/dki248. Epub 2005 Jul 22.
Zotero 插件